BIB — ProShares Ultra Nasdaq Biotechnology
Data updated: 2026-07-28
BIB — ProShares Ultra Nasdaq Biotechnology data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Leveraged · $73.65M AUM · 0.95% expense ratio · 98.5% 1-yr return. From SEC regulatory filings.
BIB Fund Overview
BIB — ProShares Ultra Nasdaq Biotechnology is a US ETF managed by Proshares Trust, categorised as Leveraged. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Proshares Trust
- Category: Leveraged
- Assets under management: $73.65M
- 1-year return: 98.5%
- Ticker: BIB
- SEC CIK: 0001174610
- SEC series ID: S000018718
- Share class ID: C000051848
BIB Holdings
Top 10 holdings of ProShares Ultra Nasdaq Biotechnology by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| ProShares GENIUS Money Market ETF | 6.80% |
| Gilead Sciences, Inc. | 4.66% |
| Vertex Pharmaceuticals, Inc. | 4.65% |
| Amgen, Inc. | 4.48% |
| Regeneron Pharmaceuticals, Inc. | 3.21% |
| Repurchase Agreement | 3.14% |
| Alnylam Pharmaceuticals, Inc. | 2.01% |
| Revolution Medicines, Inc. | 1.57% |
| Biogen, Inc. | 1.44% |
| Illumina, Inc. | 1.25% |
BIB Portfolio Allocation
Asset-class allocation of ProShares Ultra Nasdaq Biotechnology by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 63.0% |
| Derivatives | 16.0% |
| Other | 6.8% |
| Cash & Equivalents | 4.0% |
BIB Performance
Total returns for BIB (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 6.1% |
| 1 year | 98.5% |
| 3 years (annualised) | 18.5% |
| 5 years (annualised) | 0.6% |
BIB Risk Information
Risk metrics for BIB, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 27.4%
BIB Costs and Fees
BIB costs about $95 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.95%
- Gross expense ratio: 1.14%
- Portfolio turnover: 32%
- Brokerage commissions: 0.51 bps of average net assets (SEC N-CEN)
BIB Cashflows
Over the 12 months to 2026-02, ProShares Ultra Nasdaq Biotechnology had net outflows of $1.93M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$888.60K |
| 2026-01 | −$58.84K |
| 2025-12 | −$6.01K |
| 2025-11 | $6.09M |
| 2025-10 | −$36.32K |
| 2025-09 | $0 |
BIB Debt Constituents
No individual debt constituents are reported in ProShares Ultra Nasdaq Biotechnology's latest SEC N-PORT filing.
BIB Prospectus and SEC Filings
Official ProShares Ultra Nasdaq Biotechnology filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Leveraged funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.